Compare LNG & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LNG | GEHC |
|---|---|---|
| Founded | 1983 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Computer Software: Prepackaged Software |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7B | 35.8B |
| IPO Year | 1996 | 2022 |
| Metric | LNG | GEHC |
|---|---|---|
| Price | $250.31 | $72.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $268.79 | $91.17 |
| AVG Volume (30 Days) | 2.4M | ★ 2.8M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 0.90% | 0.19% |
| EPS Growth | ★ 69.93 | 4.84 |
| EPS | ★ 24.13 | 4.55 |
| Revenue | $19,976,000,000.00 | ★ $20,625,000,000.00 |
| Revenue This Year | $13.10 | $7.06 |
| Revenue Next Year | $8.05 | $4.50 |
| P/E Ratio | ★ $10.18 | $16.09 |
| Revenue Growth | ★ 27.21 | 4.84 |
| 52 Week Low | $186.20 | $57.65 |
| 52 Week High | $259.24 | $89.77 |
| Indicator | LNG | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 69.45 | 30.25 |
| Support Level | $224.24 | $72.70 |
| Resistance Level | N/A | $74.09 |
| Average True Range (ATR) | 7.95 | 2.16 |
| MACD | 0.99 | -1.06 |
| Stochastic Oscillator | 77.81 | 6.38 |
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).